161 related articles for article (PubMed ID: 11196069)
1. The mechanism of action of angiotensin II is dependent on direct activation of vascular smooth muscle carbonic anhydrase I.
Puscas I; Coltau M; Gilau L; Baican M; Pasca R; Domuta G; Hecht A
Int J Clin Lab Res; 2000; 30(3):119-25. PubMed ID: 11196069
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
[TBL] [Abstract][Full Text] [Related]
3. Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I.
Puscas L; Gilau L; Coltau M; Pasca R; Domuta G; Baican M; Hecht A
Cardiovasc Drugs Ther; 2000 Oct; 14(5):523-8. PubMed ID: 11101200
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic studies on the angiotensin II type 1 antagonists irbesartan and candesartan based on angiotensin II dose response in humans.
Belz GG; Butzer R; Kober S; Mutschler E
J Cardiovasc Pharmacol; 2002 Apr; 39(4):561-8. PubMed ID: 11904530
[TBL] [Abstract][Full Text] [Related]
5. Hypotensive effect of calcium channel blockers is parallel with carbonic anhydrase I inhibition.
Puscas I; Gilau L; Coltau M; Pasca R; Domuta G; Baican M; Hecht A
Clin Pharmacol Ther; 2000 Oct; 68(4):443-9. PubMed ID: 11061585
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
7. Peripheral sympatholytic actions of four AT1 antagonists: are they relevant for long-term antihypertensive efficacy?
Dendorfer A; Dominiak P; Tempel K; Raasch W
J Hypertens; 2005 Oct; 23(10):1861-7. PubMed ID: 16148610
[TBL] [Abstract][Full Text] [Related]
8. Vasoconstrictive drugs increase carbonic anhydrase I in vascular smooth muscle while vasodilating drugs reduce the activity of this isozyme by a direct mechanism of action.
Puscas I; Coltau M; Baican M; Pasca R; Domuta G; Hecht A
Drugs Exp Clin Res; 2001; 27(2):53-60. PubMed ID: 11392054
[TBL] [Abstract][Full Text] [Related]
9. Catecholamine-induced vasoconstriction is sensitive to carbonic anhydrase I activation.
Puscas I; Coltau M; Gilau L; Pasca R; Domuta G; Baican M; Hecht A
Braz J Med Biol Res; 2001 Mar; 34(3):339-45. PubMed ID: 11262584
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II type 1 receptor blockers.
Burnier M
Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
[No Abstract] [Full Text] [Related]
12. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
[TBL] [Abstract][Full Text] [Related]
13. Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.
Balt JC; Mathy MJ; Nap A; Pfaffendorf M; van Zwieten PA
J Cardiovasc Pharmacol; 2001 Jul; 38(1):141-8. PubMed ID: 11444497
[TBL] [Abstract][Full Text] [Related]
14. Antagonist interaction with endogenous AT(1) receptors in human cell lines.
Verheijen I; Vanderheyden PM; De Backer JP; Bottari S; Vauquelin G
Biochem Pharmacol; 2002 Oct; 64(8):1207-14. PubMed ID: 12234601
[TBL] [Abstract][Full Text] [Related]
15. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
16. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo.
Fukuhara M; Neves LA; Li P; Diz DI; Ferrario CM; Brosnihan KB
J Hypertens; 2001 Mar; 19(3 Pt 2):561-6. PubMed ID: 11327630
[TBL] [Abstract][Full Text] [Related]
17. Sympatho-inhibitory actions of irbesartan in pithed spontaneously hypertensive and Wistar-Kyoto rats.
Balt JC; Mathy MJ; Pfaffendorf M; van Zwieten PA
Fundam Clin Pharmacol; 2003 Feb; 17(1):83-91. PubMed ID: 12588634
[TBL] [Abstract][Full Text] [Related]
18. Putting the efficacy of candesartan cilexetil into perspective: a review of new comparative data.
Mallion JM; Badguet JP
J Hum Hypertens; 2000 Oct; 14 Suppl 2():S33-41. PubMed ID: 11086634
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men.
Ribstein J; Picard A; Armagnac C; Sissmann J; Mimran A
J Cardiovasc Pharmacol; 2001 Apr; 37(4):449-60. PubMed ID: 11300658
[TBL] [Abstract][Full Text] [Related]
20. Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro.
Herbert JM; Delisée C; Dol F; Schaeffer P; Cazaubon C; Nisato D; Chatelain P
Eur J Pharmacol; 1994 Jan; 251(2-3):143-50. PubMed ID: 8149971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
